The purpose of this research study is to determine if testing on blood and tissue samples, and analysis of PET/CT scans, can help researchers determine which patients are more or less likely to respond to treatment with anti-PD1 immunotherapy. Current drugs in this category include pembrolizumab and nivolumab. In the future, this information may help physicians better tailor treatment plans for their patients.
The PI of this project was: Mark Albertini, MD
This project was funded by: NIH
The term of this project was: January 2018 to November 2018
The number of subjects scanned during this project was: 4